Latest Period
Q1 2026
Security Snapshot
Perspective Therapeutics, Inc. - Common Stock (CATX) Institutional Ownership
CUSIP: 46489V302
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
136
Shares (Excl. Options)
78,563,691
Price
$4.17
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CATX on NYSE
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 78,563,691
- Total 13F value
- $327,483,394
- Portfolio coverage rank
- 0%
- Share change
- +36,458,146
- Value change
- +$156,404,058
- Number of holders
- 136
- Shares outstanding
- 113,819,077
- SEC-reported price per share
- $4.51
- Insider filing price
- $4.51
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CATX - Perspective Therapeutics, Inc. - Common Stock is tracked under CUSIP 46489V302.
- 136 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 113 to 136 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $96,742,719 to $327,483,394.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 136 institutions filings for Q1 2026.
Security key
46489V302
Latest holder period
Q1 2026
13F holders
136
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
CATX full holder history
Perspective Therapeutics, Inc. SEC filings
Perspective Therapeutics, Inc. company facts
Perspective Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 46489V302:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
CATX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $29,968,780 | 11,939,753 | Commodore Capital LP | 02 Feb 2026 | |||
| TCG Crossover GP II, LLC | 6.9% | $21,767,809 | 7,915,567 | Chen Yu | 03 Feb 2026 | |||
| Qatar Investment Authority | 6.2% | $19,451,597 | 7,073,308 | Qatar Investment Authority | 04 Feb 2026 | |||
| Avidity Partners Management LP | 5.3% | +28% | $29,523,995 | +$15,659,798 | 6,049,999 | +113% | Avidity Partners Management LP | 20 Feb 2026 |
| BlackRock, Inc. | 4.6% | $21,898,184 | 5,251,363 | BlackRock, Inc. | 31 Mar 2026 | |||
| MORGAN STANLEY | 2.6% | -57% | $13,080,088 | -$6,641,479 | 2,959,296 | -34% | Morgan Stanley | 31 Mar 2026 |
| FMR LLC | 0.4% | -98% | $824,113 | -$15,183,078 | 312,164 | -95% | FMR LLC | 28 Nov 2025 |
| JANUS HENDERSON GROUP PLC | 0% | $43,349 | 17,839 | JANUS HENDERSON GROUP PLC | 31 Dec 2024 |
As of 31 Mar 2026, 136 institutional investors reported holding 78,563,691 shares of Perspective Therapeutics, Inc. - Common Stock (CATX). This represents 69% of the company’s total 113,819,077 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
62%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 7% | 7,915,567 | 0.94% | $33,007,914 | |
| Commodore Capital LP | 5.6% | 6,336,782 | 1.5% | $26,424,381 | |
| Avidity Partners Management LP | 5.3% | 6,049,999 | +88% | 5% | $25,228,496 |
| BlackRock, Inc. | 4.7% | 5,348,561 | +17% | 0% | $22,303,498 |
| Opaleye Management Inc. | 4.1% | 4,675,000 | 0% | 2.7% | $19,494,750 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 4,378,956 | 0% | 0% | $18,260,247 |
| MILLENNIUM MANAGEMENT LLC | 3.6% | 4,046,640 | +188% | 0.01% | $16,874,489 |
| CITADEL ADVISORS LLC | 3.1% | 3,566,504 | +1219% | 0.01% | $14,872,322 |
| Affinity Asset Advisors, LLC | 2.8% | 3,164,582 | +955% | 0.77% | $13,196,307 |
| STATE STREET CORP | 2.8% | 3,132,670 | +174% | 0% | $13,063,234 |
| Balyasny Asset Management L.P. | 2.6% | 2,994,460 | 0.02% | $12,486,898 | |
| MORGAN STANLEY | 2.6% | 2,983,342 | -33% | 0% | $12,440,536 |
| Spruce Street Capital LP | 2.3% | 2,627,107 | 2.6% | $10,955,036 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,766,960 | +25% | 0% | $7,370,455 |
| Patient Square Capital LP | 1.4% | 1,625,000 | +43% | 1.2% | $6,776,250 |
| Nicholson Wealth Management Group, LLC | 1.4% | 1,618,993 | +0.06% | 3.9% | $6,751,201 |
| GOLDMAN SACHS GROUP INC | 1.1% | 1,241,816 | +677% | 0% | $5,178,373 |
| Yu Fan | 0.93% | 1,055,409 | 4.5% | $4,401,056 | |
| TWO SIGMA INVESTMENTS, LP | 0.88% | 1,003,474 | -16% | 0% | $4,184,487 |
| Ally Bridge Group (NY) LLC | 0.81% | 926,557 | 3.8% | $3,863,743 | |
| Nuveen, LLC | 0.8% | 910,221 | -29% | 0% | $3,795,621 |
| Hills Bank & Trust Co | 0.77% | 872,200 | -7% | 0.18% | $3,637,074 |
| Octagon Capital Advisors LP | 0.7% | 791,555 | 0.37% | $3,300,784 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.66% | 752,033 | 0% | 0% | $3,135,978 |
| ADAR1 Capital Management, LLC | 0.66% | 749,335 | +687% | 0.19% | $3,124,727 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 78,563,691 | $327,483,394 | +$156,404,058 | $4.17 | 136 |
| 2025 Q4 | 35,179,105 | $96,742,719 | -$20,013,129 | $2.75 | 113 |
| 2025 Q3 | 42,524,179 | $145,860,657 | +$1,461,871 | $3.43 | 103 |
| 2025 Q2 | 42,232,957 | $145,284,060 | +$679,387 | $3.44 | 95 |
| 2025 Q1 | 44,107,303 | $93,948,628 | -$10,507,953 | $2.13 | 109 |
| 2024 Q4 | 47,101,393 | $150,249,113 | -$74,925,753 | $3.19 | 133 |
| 2024 Q3 | 49,033,906 | $653,981,361 | +$116,633,428 | $13.35 | 124 |
| 2024 Q2 | 38,531,736 | $384,149,816 | +$383,863,185 | $9.97 | 102 |